Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers

International Journal of Cancer

Volumn 141, Issue 1, 2017, Pages 152-159

  Wei, Xiao Li ^a   Luo, Hui Yan ^a   Li, Chao Feng ^a   Jin, Ying ^a   Zeng, Zhao Lei ^a   Ju, Huai Qiang ^a   Wu, Qi Nian ^a   Wang, Yun ^a   Mao, Min Jie ^a   Liu, Wan Li ^a   Jia, Wei Hua ^a   Zhang, Hui Zhong ^a   Li, Yu Hong ^a   Wang, Feng ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

age; cancer; hepatitis B

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGE; ARTICLE; BILE DUCT CARCINOMA; BRAIN CANCER; BREAST CANCER; CANCER MORTALITY; CANCER TISSUE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRINKING; FAMILY HISTORY; FEMALE; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MELANOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; RESPIRATORY TRACT CANCER; SEX DIFFERENCE; SKIN CANCER; SMOKING; STOMACH CANCER; URINARY TRACT CANCER; AGED; COMPLICATION; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; LIVER TUMOR; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; RISK ASSESSMENT; VIROLOGY;

ADULT; AGE FACTORS; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 85018493673     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30719     Document Type: Article

References (37)

1. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546–55.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–73.
3. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007;109:1360–4.
4. Engels EA, Cho ER, Jee SH, Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010;11:827–34.
5. Fwu CW, Chien YC, You SL, et al. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 2011;53:1217–25.
6. Wang DS, Chen DL, Ren C, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer 2012;131:461–8.
7. Hassan MM, Li D, El-Deeb AS, et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008;26:4557–62.
8. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010–7.
9. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009;49:116–23.
10. Burki TK, Hepatitis C virus associated with high rates of cancer. Lancet Oncol 2015;16:e266.
11. Allison RD, Tong X, Moorman AC, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol 2015;63:822–8.
12. Wei XL, Qiu MZ, Jin Y, et al. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer 2015;112:1283–90.
13. Lewis R, Possible link between hepatitis B infection and gastric cancer. Lancet Oncol 2015;16:e159.
14. Ye YF, Xiang YQ, Fang F, et al. Hepatitis B virus infection and risk of nasopharyngeal carcinoma in southern China. Cancer Epidemiol Biomarkers Prev 2015;24:1766–73.
15. Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology 2014;60:2099–108.
16. Teng KY, Qiu MZ, Li ZH, et al. DNA polymerase eta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med 2010;8:126.
17. Jin Y, Gao H, Chen H, et al. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett 2013;335:447–54.
18. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. Bmc Cancer 2008;8:115.
19. Zhou Y, Zhou Q, Lin Q, et al. Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism. Int J Cancer 2013;133:1867–75.
20. Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 2010;46:1056–61.
21. Wei XL, Qiu MZ, Chen WW, et al. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med 2013;11:249.
22. Jiang XF, Tang QL, Zou Y, et al. Does HBV infection increase risk of endometrial carcinoma?. Asian Pac J Cancer Prev 2014;15:713–6.
23. Patel BB, Lipka S, Shen H, et al. Establishing the link between hepatitis B virus infection and colorectal adenoma. J Gastrointest Oncol 2015;6:492–7.
24. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22–6.
25. Squadrito G, Cacciola I, Alibrandi A, et al. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013;59:696–700.
26. Mason A, Wick M, White H, et al. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology 1993;18:781–9.
27. Blum HE, Vyas GN, Hepatitis B virus in non-hepatocytes. Lancet 1983;2:920.
28. Leung NW, Tam JS, Lau GT, et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994;73:1143–8.
29. Pasquinelli C, Laure F, Chatenoud L, et al. Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease. J Hepatol 1986;3:95–103.
30. Bouffard P, Lamelin JP, Zoulim F, et al. Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B. J Med Virol 1990;31:312–7.
31. Hyodo N, Nakamura I, Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol 2004;135:462–6.
32. Li M, Sun XH, Zhu XJ, et al. HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Lab Invest 2012;92:295–304.
33. Feld JJ, Saluja R, Truong J, et al. Hepatitis B reactivation in patients with solid tumors: a systematic review and meta-analysis. J Clin Oncol 2016;34:138.
34. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology 2015;61:703–11.
35. Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:215–9, e16-7.
36. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.
37. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261–83.